Effects of IPLEX in Myotonic Dystrophy Type 1 (DM1)

Muscle Study Group Annual Meeting
9/16/2008,
Beaver Hollow, NY

Richard T. Moxley, III, MD
Acknowledgements

University of Rochester Medical Center

- **Principal investigator:** Richard Moxley, III, MD
- **Co-investigators:** Charles Thornton, MD, Chad Heatwole, MD, Rabi Tawil, MD, Eric Logigian, MD, Stephen Welle, PhD
- **Biostatistician:** Michael McDermott, PhD
- **Clinical Evaluator:** Shree Pandya, MS, PT and Katy Eichinger, PT
- **Study coordinators:** Jim Hilbert, MS, Christine Quinn, MS and Alexis Smirnow
- **Data management:** Bill Martens.
- **Research administration:** Nancy Merriman and Tracy Forester
- **Research assistants:** Roxanne Cannarozzo and Karen Berk.
- **Neuro-Ophthalmology:** Deborah Friedman, MD

University of Texas Health Science Center, San Antonio.
- **Independent Medical Monitor:** Carlayne Jackson, MD
Acknowledgements

- NIH Wellstone Muscular Dystrophy Cooperative Research Center (MDCRC) staff, leaders, and members of the DSMB.
Muscle Wasting in DM1

- **Proposed causes:**
  - Insulin resistance, gonadal insufficiency, decreased growth hormone release.

- **Unsuccessful trials of**
  - Insulin, testosterone, and recombinant human growth factor (rhGH).

- **Promising results of rhIGF-1** (recombinant human insulin like growth factor) (Vlachopapadopoulou, 1995),
  - Improved insulin action, decreased body fat, increased plasma testosterone (n=7),
  - But, clinically significant side effects and short half-life.
Insulin Like Growth Factor 1 (IGF-1)

- Family of 6 binding proteins (BPs):
  - At least 5 of 6 BP’s form binary complex with IGF-1.
  - Ternary complex comprised of IGF-1, IGFBP-3, and an acid-labile subunit (ALS).

- 95% of circulating IGF-1 is bound to ternary complex.

- Small fraction of IGF-1 is unbound or “free” in circulation.
IGF Schematic: figure from Denley et al. (2005).
Background: IPLEX®

- IPLEX (Insmed, Inc) is rhIGF-1 complexed to rhIGF-BP3
  - Longer half-life and better safety profile compared to rhIGF-1.

- IPLEX has been well-tolerated and effective in:
  - Severe primary IGF-1 deficiency,
  - HIV associated adipose redistribution syndrome (HARS),
  - Severe insulin resistance,
  - Insulin dependent type-II diabetics,
  - Elderly women with hip fractures.
Innovative Approach

- Preparation of IGF-1 that may bypass insulin resistance and other anabolic defects that hamper muscle loss in DM1.
Study Design

- **Primary Aim**: To determine safety and feasibility of daily SC injection of IPLEX as treatment for muscle wasting and weakness in DM1.

- **Subjects**: 15 DM1 patients (21-60 yrs of age) each for initial “Dose Escalation” trial.
Design for 24 week Dose Escalation Trial of IPLEX

- IPLEX 0.5 mg/kg
- IPLEX 1.0 mg/kg
- IPLEX 1.0 mg/kg
- IPLEX 2.0 mg/kg

Off study drug

WEEKS
Cohort of Patients

- **Cohort 1**: Completed pilot study (n=6).
  - 8 weeks of 0.5 mg/kg/day and 16 weeks of 1.0 mg/kg/day of IPLEX.
  - DSMB requested that we obtain data on the relationship between blood levels of IGF-I (at 0.5 mg/kg/day and 1.0 mg/kg/day) and any adverse events before moving to a 3-step dose escalation.

- **Cohort 2**: Completed dose escalation of 0.5, 1.0, 2.0 mg/kg/day (8 weeks each) of IPLEX (n=9).
Outcome Measures

**Primary**: Safety and tolerability.

**Secondary**:  
- clinical laboratory data,
- lean body mass and fat mass (DEXA),
- muscle strength (QMA and MMT),
- myotonia (grip and electrically evoked),
- IGF-1, IGF-2, and IGF-BP3 levels,
- gastrointestinal and cognitive measurements.
Timeline

- **2003-2005**
  - Completed start-up procedures, manual, etc.

- **2005-2007**
  - Enrolled patients.

- **September 2007**
  - Presented at the 6th International Myotonic Dystrophy Consortium (IDMC) Meeting;
  - Presented preliminary data on the first 6 patients.

- **April 2008**
  - Completed all treatment and post-treatment visits.
Results

- Adverse Events and safety profile.
- Total and free IGF values.
- Muscle mass as measured by DEXA.
Adverse Events (AE)

- 1 serious AE (SAE) occurred in the off-drug phase:
  - deemed unrelated (gallbladder removed).

- No SAEs related to study drug.

- 1 moderate, possibly related AE:
  - papilledema and intracranial hypertension that resolved without sequelae.
Adverse Events

- 103 mild AEs:
  - 42% (n=44/105) were not related,
  - 45% (n=47/105) were possibly related,
  - 13% (n=14/105) were probably related.

- 14 AEs probably related to study drug:
  - 2 AEs of light headedness,
  - 3 AEs of hypoglycemia,
  - 9 injection site reactions (n=8 patients).
Safety Profile

- Of the 9 injection site reactions,
  - 7 occurred at first dose (0.5 mg/kg/day);
  - 2 occurred at second dose (1.0 mg/kg/day);
  - 0 occurred at third dose (either 1.0 or 2.0 mg/kg/day).

- Laboratory and imaging results indicated IPLEX was safe and well tolerated.
Total IGF-1 values

Fig 1: Mean total IGF-I levels analyzed. Mean normative range indicated as dashed line; 100 – 308ng/mL (Esoterix).
Free IGF-1 values

Fig 2: Mean free IGF-I levels analyzed to date. Mean normative range indicated as dashed line; 0.65 – 5.2ng/mL (Juul et al., 1997).
Lean Muscle Mass: Cohort 1

Fig 3: Change in mean lean muscle mass (g) compared to baseline and measured by Dual Energy X-ray Absorptiometry (DEXA) (n=6). * p<0.05
Lean Muscle Mass: Cohort 2

Fig 4: Change in mean lean muscle mass (g) compared to baseline and measured by Dual Energy X-ray Absorptiometry (DEXA) (n=9). * p<0.05

![Graph showing changes in lean muscle mass over time.](image-url)
Summary

- IPLEX was safe and well-tolerated in DM1 (n=15 patients).

- Encouraging trends in a variety of endpoint measures, including patient reported outcomes.
A Catalyst For Future Study

- These initial pilot studies have led to a multi-center collaborative study using methods established by our NIH Wellstone MDCRC dose escalation trial.
Phase II Trial

- Led by Insmed, Inc, with funding through Insmed and Muscular Dystrophy Association (MDA) Translational Research Corporate Grant.

- 12 sites participating in the randomized, placebo-controlled, double-blind clinical study of IPLEX in ~70 DM1 patients.
Study Design

Endpoints:
- Endurance
- Ambulation
- Cognitive function
- Insulin resistance
- Cholesterol and triglycerides
- Muscle function and strength
- Pain
- Gastrointestinal function
- Quality of life

IPLEX 1.0 mg/kg/day or placebo

WEEKS

0 4 8 12 16 20 24
Progress and Collaborations

- Current Phase II trial is beyond the scope of traditional Wellstone funding.
- NIH Wellstone MDCRC funding has nurtured collaboration between industry, patient advocacy groups, and medical centers.
- What other studies can develop?
Future Questions

What measures of IGF-1 and/or related proteins best indicate a therapeutic response?

- Additional measures may include other IGF BPs, sex steroid BP, growth hormone, and other pituitary-hypothalamic axis hormones.

What are the best endpoint measures in our optimal dose treatment trial?
Extra slides, drafts
Lean Muscle Mass (Cohort 1)

Fig 2: Mean lean muscle mass (kg) as measured by Dual Energy X-ray Absorptiometry (DEXA) (n=5 for week 24; n=6 all other weeks).

On IPLEX

Off IPLEX

<table>
<thead>
<tr>
<th>Week</th>
<th>Lean Mass (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>43.8</td>
</tr>
<tr>
<td>8 wks</td>
<td>44.5</td>
</tr>
<tr>
<td>16 wks</td>
<td>44.9</td>
</tr>
<tr>
<td>24 wks</td>
<td>46.9</td>
</tr>
<tr>
<td>Post 4 wks</td>
<td>44.5</td>
</tr>
<tr>
<td>Post 16 wks</td>
<td>43.5</td>
</tr>
</tbody>
</table>
Lean Muscle Mass (change each visit)

Fig 2: Mean lean muscle mass (kg) as measured by Dual Energy X-ray Absorptiometry (DEXA) (n=5 for week 24; n=6 all other weeks).